How many insider trades does FilingIQ track for ABUS?

FilingIQ tracks 94 Form 4 insider transactions for ABUS (Arbutus Biopharma Corp), covering filings from Jul 9, 2015 onwards. 2 of those were filed in the last 90 days.

Are ABUS insiders net buyers or net sellers?

Across the full Form 4 history for ABUS, 9 transactions (10%) were open-market purchases and 24 (26%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ABUS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ABUS in?

Arbutus Biopharma Corp (ABUS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $857.77M.

ABUS insider trading

NasdaqGS Healthcare

Arbutus Biopharma Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

10% / 26%

Market cap

$857.77M

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Company website: www.arbutusbio.com

ABUS insider activity at a glance

FilingIQ has scored 94 insider transactions for ABUS since Jul 9, 2015. The most recent filing in our index is dated Jun 8, 2026.

Across the full history, 9 open-market purchases and 24 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ABUS insider trades is 56.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ABUS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,223

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 152

Guardant Health, Inc.

KalVista Pharmaceuticals, Inc.

KNSA 129

Kiniksa Pharmaceuticals International, plc

Frequently asked

How many insider trades does FilingIQ track for ABUS?: FilingIQ tracks 94 Form 4 insider transactions for ABUS (Arbutus Biopharma Corp), covering filings from Jul 9, 2015 onwards. 2 of those were filed in the last 90 days.
Are ABUS insiders net buyers or net sellers?: Across the full Form 4 history for ABUS, 9 transactions (10%) were open-market purchases and 24 (26%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ABUS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ABUS in?: Arbutus Biopharma Corp (ABUS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $857.77M.

Methodology & sources

Every ABUS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.